Computational Neuropharmacology Lab

Developing novel, fast-acting neurotherapeutics by targeting the TrkB receptor via computational chemistry and in-silico screening. Focused on engineering high-affinity benzoxazole derivatives to induce rapid neuroplasticity and bridge the critical therapeutic delay in major depressive disorder

Description

Team

0xcbe7f…96a6f

Owner

Project Score

Updated Sep 13, 2026

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Project Progress

All updates

All categories

Timeline

Computational Neuropharmacology Lab

Description

Team

0xcbe7f…96a6f

Owner

Project Score

Updated Sep 13, 2026

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

Project Progress

All updates

All categories

Timeline

Rationale

The project is entirely computational with no wet-lab experimental work conducted. All evidence consists of in silico molecular docking, SAR analysis, and molecular dynamics simulations. The project explicitly states "All work is computational (in silico); no wet-lab experimental data is reported," and no binding assays, cell-based assays, or animal studies have been performed. Per the classification decision tree, the answer to Question 1 ("Has ANY experimental laboratory work been conducted?") is NO, which places this project squarely at TRL 1. Pure computational work without wet-lab validation remains TRL 1 per the edge case guidance.

Assessment

Low Confidence

RecommendationSUPPLEMENT

Total Score3.60

Overall Assessment

The B1 orthoMe project receives a final weighted score of 3.60 out of 5.00, reflecting a solid early-stage (TRL 1–2) computational drug discovery program with clear strengths and identifiable gaps. The strongest dimension is therapeutic relevance (score 4/5, weighted 2.40): the TrkB neurorestorative mechanism is scientifically well-grounded, and the replicated MD evidence is methodologically rigorous for this stage, demonstrating reproducible binding-site engagement superior to the benchmark. The main limitation is the absence of any experimental validation — all data is in silico. Intellectual property scores moderately (3/5, weighted 0.75): while the compound appears novel, TrkB is a competitive target space and no freedom-to-operate or prior art analysis is presented. Therapeutic optionality also scores moderately (3/5, weighted 0.45): TrkB relevance spans multiple CNS indications, but the concept is narrowly CNS-focused with no demonstrated cross-therapeutic applicability. Key recommendations for score improvement include: (1) generating in vitro binding/functional data to validate the computational predictions, (2) conducting a formal IP landscape and freedom-to-operate analysis, (3) quantifying TrkB/TrkA/TrkC selectivity to strengthen both the therapeutic and IP narratives, and (4) exploring whether the B1 scaffold could address non-CNS Trk-related indications to broaden optionality. Overall, this is a promising early-stage program with a well-executed computational foundation that now requires experimental de-risking to advance.

Weighted Score

Therapeutic Relevance

The mechanism targeting TrkB (tropomyosin receptor kinase B) is scientifically plausible and biologically relevant. TrkB is a well-established neurotrophin receptor involved in neuronal survival, plasticity, and CNS neurorestorative pathways, making it a credible therapeutic target for neurodegenerative and neuropsychiatric diseases. The computational evidence is methodologically sound: replicated 2 ns MD simulations show reproducible pocket engagement (100% contact occupancy), strong H-bond persistence (95% of frames), and superior ligand retention (lower RMSD) compared to the benchmark. The SAR-driven optimization and maintenance of CNS-like physicochemical space further support scientific plausibility. However, the score is capped at 4 rather than 5 because all evidence is purely in silico — no wet-lab binding assays, functional data, or in vivo proof-of-concept exist yet. Additionally, no quantitative selectivity data (e.g., IC50 ratios for TrkB vs. TrkA/TrkC) are reported, and the 2 ns MD timescale is relatively short, leaving uncertainty about longer-timescale binding stability.

Therapeutic Optionality

There is moderate therapeutic optionality. TrkB signaling is implicated across multiple CNS conditions — neurodegenerative diseases (Alzheimer's, Parkinson's), depression, neuropathic pain, and traumatic brain injury — providing reasonable breadth of potential therapeutic applications from a single mechanism. The B1 scaffold series with multiple analogs (orthoMe, diF B, H, orthoCl) suggests some chemical flexibility for optimization toward different profiles. However, the concept is fairly narrowly focused on a single receptor family (Trk receptors) within the CNS space. No evidence of applicability outside the CNS is presented, and the selectivity context (TrkB/TrkA/TrkC) remains unquantified, limiting the ability to assess whether the compound could be tuned for different Trk-related indications. The optionality is conceptual rather than demonstrated at this stage.

Intellectual Property

The B1 orthoMe compound appears to be a novel chemical entity within a proprietary scaffold series, and the specific SAR-driven modifications (ortho-methyl substitution pattern) combined with the computational evidence of superior TrkB binding could support a patent filing around composition of matter or method of use. The systematic ranking of five analogs and the documented structure-activity relationships strengthen the IP narrative. However, TrkB is a well-known and actively pursued target in the neuroscience space, with existing literature and competing programs (e.g., small molecule TrkB agonists/modulators from other groups). The document does not discuss freedom-to-operate analysis, prior art landscape, or existing patents on TrkB-targeting compounds. Without knowing the specific chemical structure details of the B1 scaffold, it is difficult to fully assess novelty risk. The score of 3 reflects a reasonable but unconfirmed IP position — novel enough to potentially patent but with meaningful competitive and prior art risks in the TrkB space.